T Cell Engagers 1

• 1609 · PDF Unlocking pMHC target space for next generation T cell engagers in oncology and autoimmunity Roberto Magliozzi, Haydn Prosser, Hanif Ali, Amy Li, Luca Pellegrinet, Ni Huang, Petra Mlcochova, Wei Wang, Ruben Cabanillas, E-Chiang Lee, Allan Bradley
• 1610 · PDF A novel and versatile Prodrug T cell engager platform with a novel candidate demonstrating potent and tumor-restricted activity Zhou Lv, Yinhui Ding, Jingjing Mao, Huifeng Lv, Yang Yang, Yi Ren, Yu Zhang, Lijun Wang, Danqing Wu, Xuan Wu, Shiyong Gong
• 1611 · PDF Development of a T cell engager against IGFBPL1: A novel target for small cell lung cancer and other neuroendocrine cancers Lauren A. Pitt, Eleanor Leung, Ruban Kannan, Shereen Jabar, Nicole Church, Zariah Rosenes, Ben Kiefel, Matthew Beasley
• 1612 · PDF Novel CD3 binders enable T cell engagers with potent tumor control, limited cytokine release, and safe pairing with co-stimulation Sinduja Marx, Ian Blumenthal, Kristina Pilat, Shelli M. Morris, Emily J. Girard, Kenneth Brasel, Ray Ruff, Alison M. Williams, Hailey Hentschel, Steven Chen, Chunfeng Yin, James M. Olson, Jason Price
• 1613 · PDF Expanded therapeutic window of potent bispecific PD-L1:CD3 T cell engager using a novel best-in-class CD3 binder Andrew J. Mhyre, Emily J. Girard, Sinduja Marx, Shelli M. Morris, Kristina Pilat, Alison M. Williams, Parvathi Muthuraman, Ray Ruff, Hailey Hentschel, Steven Chen, Chunfeng Yin, Zachary Crook, Jason Price, James M. Olson
• 1614 · PDF Novel anti-CD3 single domain antibodies for the development of T cell engager Jieying Liu, Yongqing Cheng, Mengmeng Sun, Xiaoqian Zhang, Hui Cong, Rumeng Bao, Changchang Zhang, Yu Dan, Shuang Wang, Jie Yang, Donghui Wu, Lei Wu, Jijie Gu
• 1615 · PDF Discovery of CD28 targeting single domain antibodies to facilitate the development of costimulatory T cell engager Siwei Nie, Yali Wan, Hang Zhou, Xinyan Ji, Jianqing Xu, Lei Wu, Jijie Gu
• 1616 · PDF CLSP-5282, a first-in-class T cell engager targeting KRas G12V mutant peptide presented on HLA-A*03:01 Amanda Ford, Lenore Cullen, Alec R. Andrews, Justina X. Caushi, Catherine Souza, Veselin S. Dobrev, Raffaello Verardi, Hayden Jones, Brena Williams, Kai Li Tan, Michael Alloway, Anthony S. Gizzi, James Bingham, Gillian A. Kingsbury, Jessica Kohler
• 1617 · PDF AI-assisted development of a TCR-like T cell engager targeting MAGE-A4 against melanoma Yang Liu, Qi Zhao
• 1618 · PDF A novel pan-gamma-delta T cell engager platform for next-generation cancer therapeutics Baotian Yang, Yuan Wu, Tengfei Yu, Sha Cheng, Qun Sun, Siwei Nie, Lei Wu, Jijie Gu
• 1619 · PDF Discovery and optimization of XTX601, a masked claudin 18.2-targeting T cell engager Jason Hedges, Pyae Hein, David Crowe, Aaron Bogle, Jing Ying Eng, Manoussa Fanny, Wilson Guzman, Sami Kahloun, Bernard Lanter, Janice Lee, Natalia Malkova, Haley Saxton, Kyle Smith, Sallyann Vu, Yihong Zhang, Kurt Jenkins, Elsie DiBella, Benjamin Nicholson, Scott Coleman, Carl Uli Bialucha
• 1620 · PDF ATG-112, a novel ALPP/G x CD3 bispecific T cell engager, for the treatment of ALPP/G + solid tumors Jishun Chen, Yu Bai, Suya Bai, Huiling Liu, Zaoshun Hu, Jay Mei, Peng Chen, Bing Hou
• 1621 · PDF ATG-106, a novel “2+1”format CDH6-targeted T-cell Engager (TCE), shows potent T cell dependent cytotoxicity and in vivo anti-tumor efficacy Tengteng Li, Peng Chen, Huiling Liu, Zaoshun Hu, jiaqi yan, jie huang, Jay Mei, Bing Hou
• 1622 · PDF The affinity-optimized bispecific T cell engager W308051 selectively kills PSMA-expressing tumor cells with limited cytokine secretion Johannes Breuning, Yi Qin, Yunying Chen, Xia Wang, Jijie Gu
• 1623 · PDF A novel pH dependent T cell engager platform for next generation cancer therapeutics Jie Li, Wenqian Fang, Nan Feng, Tengfei Yu, Siwei Nie, Lei Wu, Jijie Gu
• 1624 · PDF Logic-gated switch-DARPin T cell engager with CD2 co-stimulation for improved safety and efficacy in MSLN and EpCAM co-expressing ovarian cancer Matteo Bianchi, Sarah Jetzer, Simon Häberle, Aline Eggenschwiler, Albulena Toska, Anja Schlegel, Justin D. Walter, Stephan Wullschleger, Tamara Lekishvili, Yvonne Kaufmann, Rocio Evangelista Vaz, Marcela Guzman Ayala, Alexander Link
• 1625 · PDF VHH nanobody-masked conditionally active CDH17 T cell engager for colorectal cancer Lei Wu, Guoxin Ni, Xiaoyue Liu, Sha Cheng, Senfeng Xiang, Yi Liu, Xia Wang, Donghui Wu, Tengfei Yu, Jijie Gu
• 1626 · PDF A novel machine-learning derived nectin-4 x CD3 bispecific T-cell engager, LGTX-101, demonstrates high degrees of tumor selectivity and potently induces tumor regression in vivo Lucrecia Alberdi, Sabrina Bouhafs, Dan Foxler, Justin Grace, Winston Haynes, Catherine Howsham, Leo Kassimatis, Sylwia Marshall, Lida Mavrogonatou, James McClory, Portia McGhan, Rebecca Mighell, Michael Mullin, Sandra Pasternakiewicz, Sujata Ravi, Nush Sarvaria, Gino Van Heeke, Angus Sinclair
• 1627 · PDF DS-2243a, an HLA-A*02/NY-ESO-directed bispecific T‑cell engager, shows potent anti-tumor activity in preclinical models of solid tumors Junya Ichikawa, Ayaka Yatsu, Ryuichi Nakamura, Akemi Kita, Shingo Noguchi, Yoko Ishimoto, Chikako Maru, Kento Tanaka, Kensuke Nakamura, Shinji Furuzono, Makiko Nakayama, Toshiaki Ohtsuka, Reimi Kawaida
• 1628 · PDF A bispecific PDL1:CD3 T-cell engager potently kills intractable primary and metastatic intracranial tumors Emily J. Girard, Shelli M. Morris, Kristina Pilat, Alison M. Williams, Kenneth Brasel, Heather Conti, Parvathi Muthuraman, Ray Ruff, Hailey Hentschel, Steven Chen, Chunfeng Yin, Zachary Crook, Jason Price, Andrew J. Mhyre, James M. Olson
• 1629 · PDF An innovative approach to improve bispecific T-cell engagers for solid tumor therapy Hing C. Wong, Xiaoyun Zhu, Varghese George, Hamidreza Farzaneh, Crystal Gilkes, Natalia Valderrama, Alyssa Thompson, Lijing You, Lucas Gomez, Christian Echeverri, Niraj Shrestha, Peter R. Rhode, Jack Egan
• 1630 · PDF Preclinical investigation of a novel tumor associated antigen, cb02, as a bispecific t-cell engager in cancer Mary Mathieu, Daniel Reiton, Kevin Nuno, Egle Jurgaityte, Jason Chen, Nathan Fisher, Prasuna Paluru, Robert Chen, Ralph McAnelly, Colton Bracken, Jen Chew, Javeria Haroon, Maeve O'Huallachain, Maggie Lu, Jeffrey Verboon, Max Mumbach, Alexander Martinko, David Kugler, Dan Rock, Burcu Yigit
• 1631 · PDF Leveraging off-the-shelf T cells to enhance bispecific T cell engager therapy efficacy in patients with suboptimal T cell responses Saghar Pahlavanneshan, Stephen J. Forman, Xiuli Wang
• 1632 · PDF Preclinical characterization of DBXO-1, a multi-pMHC targeted bispecific T cell engager for major solid tumors Johanna K. Kaufmann, Jason Lajoie, John L. Silberstein
• 1633 · PDF MAIT engagers: Avoiding Treg suppression to deliver stronger activity in solid tumors. Simon E. Plyte, Marie Fraudeau, Dorothee Winterberg, Claire Germain, Camille Rousseau, Maxime Audin, Alexandre Ivagnes, Sothea Touch Dumoitier, Sarah Ducellier, Lise Fenou, Hans Heinrich Oberg, Pierre Emmanuel Gerard, Isabelle Teulon, Daniela Wesch, Matthias Peipp, Julie Prigent
• 1634 · PDF A conditionally-active, dual-targeting TCE with superior tumor selectivity for the treatment of solid tumors Steffen Dickopf, Jorge A. Lerma Romero, Jessica Seib, Laura Perucho-Aznar, Steffen Runz, Abdul-Habib Maag, Anna Pryszlak, Anja Schreiber, Martha Gschwandtner, Christoph Erkel, Richard J. Austin
• 1635 · PDF CBX-663, a first-in-class TCR-mimetic T-Cell Engager targeting the TERT peptide-HLA complex, mediates potent cytotoxicity in vitro and tumor inhibition in vivo in preclinical models of solid malignancies Yu Huang, Ricard Masia, Bhupal Ban, Qunyan Yu, Jennifer Helble, Jessica Jimenez, Delainey O’Connor, Preethi Sankaran, Christine A. Devlin, Melissa Bikowitz, Emily McNally, Sarah Jaffe, Tanzila Rahman, Alona Kulesha, Andrew Wolpert, Shawn O’Malley, Yue Li, Michael Jennings, Galina Gabriely, Mathilde A. Poussin, Daniel J. Powell, Nga Sze Amanda Mak, Tao Wang, Geraldine L. C. Paulus, Michi Schebesta, Benjamin Lee, Dmitri Wiederschain
• 1636 · PDF TNF-driven paracrine killing determines the cytotoxic efficacy of Teclistamab in Myeloma Allison Carr, Elise Sintim-Aboagye, Adrian Ting
• 1637 · PDF Human-cynomolgus cross-reactive CD3 nanobody-centric TCE platform enhances clinical translation Yuanyuan Wang, Ce Gu, Liang Xiao, Huijuan Lu, Ruhan Lin, Tingchu Wu, Peipei Hu, Chang Zhou, Fan Wu, Jian Guo, Yongting Huo, Di Lu
• 1638 · PDF A high-throughput luciferase cancer cell panel driving DLL3-targeted TCE discovery Chen Cai, Yue Zhai, Kejun Mao, Yixiao Zhao, Mingying Li, Qian Wang, Yan Zhang, Lili Chai, Tj (Tiejun) Bing

在完整检索应用中浏览本分会场 →